MXPA05013433A - Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato. - Google Patents

Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato.

Info

Publication number
MXPA05013433A
MXPA05013433A MXPA05013433A MXPA05013433A MXPA05013433A MX PA05013433 A MXPA05013433 A MX PA05013433A MX PA05013433 A MXPA05013433 A MX PA05013433A MX PA05013433 A MXPA05013433 A MX PA05013433A MX PA05013433 A MXPA05013433 A MX PA05013433A
Authority
MX
Mexico
Prior art keywords
amoxicillin
clavulanante
pharmaceutical formulations
formulations
clavulanate
Prior art date
Application number
MXPA05013433A
Other languages
English (en)
Inventor
Jill Tracy Rickman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0313913.6A external-priority patent/GB0313913D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MXPA05013433A publication Critical patent/MXPA05013433A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulaciones que comprenden amoxicilina y clavulanato para reconstitucion en una suspension acuosa incorporan bajos niveles de carboximetilcelulosa de sodio para estabilizar el pH de las mismas.
MXPA05013433A 2003-06-16 2004-06-15 Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato. MXPA05013433A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47876903P 2003-06-16 2003-06-16
GBGB0313913.6A GB0313913D0 (en) 2003-06-16 2003-06-16 New use
PCT/EP2004/006551 WO2004110441A1 (en) 2003-06-16 2004-06-15 Pharmaceutical formulations comprising amoxicillin and clavulanate

Publications (1)

Publication Number Publication Date
MXPA05013433A true MXPA05013433A (es) 2006-03-09

Family

ID=33420899

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013433A MXPA05013433A (es) 2003-06-16 2004-06-15 Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato.

Country Status (13)

Country Link
EP (1) EP1491195A1 (es)
JP (1) JP2006527726A (es)
KR (1) KR20060010838A (es)
AU (1) AU2004246811A1 (es)
BR (1) BRPI0411524A (es)
CA (1) CA2529102A1 (es)
CO (1) CO5640085A2 (es)
IL (1) IL172096A0 (es)
MA (1) MA27850A1 (es)
MX (1) MXPA05013433A (es)
NO (1) NO20055882L (es)
RU (1) RU2343931C2 (es)
WO (1) WO2004110441A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007002924A1 (de) * 2007-01-19 2008-07-24 Bayer Healthcare Ag ß-Lactam-haltige Formulierungen mit erhöhter Stabilität in wässriger Lösung
WO2013106601A1 (en) * 2012-01-10 2013-07-18 Michael Spector Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and method for using same
CN114668724B (zh) * 2020-12-24 2023-08-22 鲁南制药集团股份有限公司 一种阿莫西林克拉维酸钾干混悬剂及其制备方法
CN114886893B (zh) * 2021-07-30 2023-09-29 江苏恒丰强生物技术有限公司 一种复方阿莫西林粉及其制备方法
CN116327760A (zh) * 2022-12-26 2023-06-27 南京臣功制药股份有限公司 一种阿莫西林克拉维酸钾缓释干混悬剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100499812B1 (ko) * 1997-02-14 2005-07-08 스미스클라인 비참 코포레이션 아목시실린 및 클라불라네이트를 포함하는 약제학적 제형
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
ES2269063T3 (es) * 1999-08-20 2007-04-01 Laboratoire Glaxosmithkline S.A.S. Formulacion farmaceutica que comprende amoxiciclina y clavulanato.

Also Published As

Publication number Publication date
EP1491195A1 (en) 2004-12-29
CO5640085A2 (es) 2006-05-31
AU2004246811A1 (en) 2004-12-23
BRPI0411524A (pt) 2006-08-01
CA2529102A1 (en) 2004-12-23
WO2004110441A8 (en) 2005-03-17
JP2006527726A (ja) 2006-12-07
RU2343931C2 (ru) 2009-01-20
RU2005138127A (ru) 2006-07-27
KR20060010838A (ko) 2006-02-02
NO20055882L (no) 2005-12-28
WO2004110441A1 (en) 2004-12-23
IL172096A0 (en) 2009-02-11
MA27850A1 (fr) 2006-04-03

Similar Documents

Publication Publication Date Title
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
SG150550A1 (en) Pharmaceutical preparation containing an antibody for the egf receptor
AU2002331391A1 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
AU2003267203A1 (en) Method for administering thermotherapy to prevent the growth of tumors
AU2003238023A1 (en) Method of evaluating myelosuppressive state
AU2002953073A0 (en) Amplification of biotin-mediated targeting
TW200501947A (en) Stabilized pharmaceutical composition comprising an amorphous active substance
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
BR0015256A (pt) Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano
TNSN05222A1 (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid
YU3101A (sh) Farmaceutska formulacija suspenzije koja obuhvata amoksicilin, klavulonsku kiselinu i celulozu
MX2007010930A (es) Formulacion de aviptadil.
NO20055882L (no) Farmasoytiske formuleringer omfattende amoksicillin og klavulanat
SG162766A1 (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
TW200509990A (en) Pharmaceutical formulations
GEP20125525B (en) Stable liquid pharmaceutical composition based on trazodone
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
DE60322228D1 (de) Schnell zerfallende tablette
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
AU2003246566A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
ATE350064T1 (de) Pharmazeutische zusammensetzungen von rapamycines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal